AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25534580
Drug: Oscillating positive
RxNorm normalized name: AerobiKA Oscillating Positive Expiratory Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating positive expiratory pressure (PEP) device, thrice daily for 5 postoperative days
Trial: 20945323
Drug: Romiplostim 750
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim 750 μg administered subcutaneously weekly or biweekly
Trial: 20945323
Drug: Romiplostim 750
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim 750 μg administered biweekly intravenous injections
Trial: 20945323
Drug: Weekly subcutaneous
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections
Trial: 12654706
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg perindopril/0.625 mg indapamide
Trial: 12654706
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily enalapril
Trial: 8805730
Drug: Streptokinase (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (1.5 million units intravenously in 100 mL of normal saline over 1 hour)
Trial: 1385635
Drug: Triple antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antibiotics (ampicillin plus clindamycin plus gentamicin)
Trial: 25943368
Drug: Deferiprone (DFP)
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone (DFP) treatment for 6 to 12 months
Trial: 25943368
Drug: Deferiprone (DFP)
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone (DFP) treatment for 6 months
Trial: 25943368
Drug: Deferiprone (DFP)
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone (DFP) treatment
Trial: 18246677
Drug: Acupuncture, Danshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture, Danshen Zhushe Ye (Saliva Injection), and routine western drugs
Trial: 7641716
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg initial dose, with repeat doses of 50 mg as needed up to 400 mg total
Trial: 7641716
Drug: Morphine 5
RxNorm normalized name: ethylmorphine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 5 mg initial dose, with repeat doses of 5 mg as needed up to 40 mg total
Trial: 2744062
Drug: Nitrendipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (mean final dose 55 mg/day)
Trial: 23860021
Drug: Red yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red yeast rice capsules 600 mg twice a day for 8 weeks
Trial: 20112482
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Baihui (GV 20), Fengchi (GB 20), Shuaigu (GB 8), Xingjian (LR 2), Neiguan (PC 6), Sanyinjiao (SP 6) combined with oral administration of Chinese herbal decoction
Trial: 20112482
Drug: Simple oral
RxNorm normalized name: Simple Oral Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple oral administration of Chinese herbal decoction
Trial: 17686346
Drug: Pharmaceutical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical treatments for fatigue in MS patients
Trial: 17686346
Drug: Non-pharmaceutical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmaceutical treatments for fatigue in MS patients
Trial: 12494285
Drug: Transdermal needle-free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal needle-free injection of alprostadil
Trial: 12494285
Drug: Intracavernosal needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal needle injections of alprostadil
Trial: 12494285
Drug: Needle-free injection
RxNorm normalized name: Stratis Needle-Free Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-free injection
Trial: 12494285
Drug: Needle-tipped injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-tipped injection
Trial: 9819795
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Cytosine arabinoside (Ara‐C) (100 mg/m2/d, days 1‐7) and idarubicin (Ida) (12 mg/m2/d, days 1‐3) for induction; Ara‐C (200 mg/m2/d, days 1‐6) and Ida (15 mg/m2/d, day 1) twice for consolidation.
Trial: 9819795
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Ara‐C (200 mg/m2/d, days 1‐10), daunorubicin (Dnc) (50 mg/m2/d, days 1, 3, 5) and etoposide (VP16) (100 mg/m2/d, days 1‐5) for induction; consolidation therapy with Ara‐C on days 1‐8 and additional regimens.
Trial: 29175466
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with 0.01% Methylene Blue and red laser, λ660 nm, 3J energy per point
Trial: 29175466
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) with λ660 nm, 1J energy per point
Trial: 26966058
Drug: Tianjiu therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianjiu therapy applied at three points (conception vessel 4, and bilateral kidney 1) during each HD session for 4 weeks.
Trial: 26966058
Drug: Clay patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clay patches applied in the same way as those in the Tianjiu treatment group for 4 weeks.
Trial: 26966058
Drug: Tianjiu therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianjiu therapy
Trial: 26966058
Drug: Clay patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clay patches
Trial: 19926782
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg/day for 6 weeks followed by 8 mg/day for 6 weeks)
Trial: 7562885
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg for 1 month, 20 mg for 1 month, 40 mg for 4 months (once daily in the evening)
Trial: 2196107
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with methotrexate, cisplatin, and continuous infusion 5-fluorouracil (MPF) (arm A)
Trial: 2196107
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with bleomycin, cisplatin, and methotrexate (PBM) alternating with cisplatin and 5-FU (PF) (arm B)
Trial: 23786763
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (ICBT) with MoodGYM
Trial: 3528223
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg folic acid daily
Trial: 29722833
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil (2.3 g daily)
Trial: 27168163
Drug: TRPV1 antagonist
RxNorm normalized name: Tetrahydronaphthyl urea based selective TRPV1 antagonist
DrugBank: XEN-D0501 (DB18673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRPV1 antagonist ID1609
Trial: 9114206
Drug: Sulbactam/cefoperazone (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam/cefoperazone (2-4 g/d) administered in evenly divided doses every 12 hours by a 30-minute intravenous drip
Trial: 9114206
Drug: Cefotaxime (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (6-12 g/d) administered in evenly divided doses every 6 or 8 hours by a 30-minute intravenous drip
Trial: 30281805
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol (2 mg/d)
Trial: 30281805
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (100 µg/d)
Trial: 27765686
Drug: 10% sucralfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sucralfate ointment (every 12 hours)
Trial: 20049522
Drug: Non-woven textile
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-woven textile material (modified tampon) for vaginal drug delivery
Trial: 12453372
Drug: Amoxicillin or
RxNorm normalized name: amoxicillin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin or clarithromycin (Group 2)
Trial: 11188778
Drug: IVIG (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (intravenous immunoglobulin) 0.15-0.2 g/kg bodyweight monthly for 2 years
Trial: 3326525
Drug: Ketoconazole 1200
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole 1200 mg
Trial: 3326525
Drug: Ketoconazole 1600
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole 1600 mg
Trial: 3326525
Drug: Ketoconazole (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (various doses)
Trial: 31711306
Drug: Experimental therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapy (50% efficacious)
Trial: 31711306
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (80% efficacious)
Trial: 29659178
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of botanically sourced caffeine from 480 mg of green coffee bean extract
Trial: 29659178
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of synthetic USP caffeine
Trial: 20096510
Drug: Extended cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended cognitive behavioral treatment
Trial: 12878335
Drug: Usual nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual nutritional rehabilitation program + 5 g x d(‐1) of spiruline
Trial: 1858500
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied vaginal tablet of 150 mg econazole
Trial: 1858500
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered capsule of 150 mg fluconazole
Trial: 19942723
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional expectant treatment)
Trial: 9834926
Drug: High-complex-carbohydrate, low-fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-complex-carbohydrate, low-fat formulation (HCF)
Trial: 9834926
Drug: Low-carbohydrate formulation
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate formulation (RCF)
Trial: 24667592
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum 299 v (5 × 10 colony forming units daily)
Trial: 27706045
Drug: Erythropoietin (33,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (33,000 IU IV daily for three days)
Trial: 25342049
Drug: Meal 2
RxNorm normalized name: colloidal oatmeal 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal 2 (meal 1 mixed with 9 g guar)
Trial: 18212755
Drug: Gemcitabine 1200
RxNorm normalized name: gemcitabine 1200 MG in 120 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1200 mg/m² on days 1 and 8 every 3 weeks for three courses followed by docetaxel 37.5 mg/m² on days 1 and 8 every 3 weeks
Trial: 4039588
Drug: Neobiphyllin (TPD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neobiphyllin (TPD) - 800 mg, infused for 20 min
Trial: 4039588
Drug: Theophylline-ethylendiamine (TE)
RxNorm normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline-ethylendiamine (TE) - 480 mg, short-infusion for 20 min
Trial: 27796434
Drug: Conventional hard‐shelled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hard‐shelled gelatin capsule
Trial: 25601917
Drug: Subcutaneous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous low-dose unfractionated heparin (LDUH) 125 U/kg per day in three divided doses (Group B)
Trial: 25601917
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) 6000 IU once a day (Group C)
Trial: 25601917
Drug: LMWH 4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH 4000 IU twice daily (Group D)
Trial: 11245321
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefotiam (study group, n=76)
Trial: 9730793
Drug: MDPI (beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDPI (beclomethasone dipropionate) 400 microgram twice daily
Trial: 9730793
Drug: MDI-spacer (beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI-spacer (beclomethasone dipropionate) 400 microgram twice daily
Trial: 8044729
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate depot injection used alone
Trial: 22416440
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus ivabradin
Trial: 15519705
Drug: Hib vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib vaccination (1 dose)
Trial: 15519705
Drug: Hib vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib vaccination (2 doses)
Trial: 15519705
Drug: Hib vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib vaccination (3 doses)
Trial: 10128359
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) administered in PVC containers
Trial: 10128359
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) administered in glass containers
Trial: 3310905
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of prochlorperazine, metoclopramide and dexamethasone
Trial: 26840331
Drug: Resveratrol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (200 mg/day)
Trial: 24432995
Drug: Tianqi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianqi capsule for 12 months
Trial: 23899039
Drug: Three-monthly monitoring
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-monthly monitoring
Trial: 19912490
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection (ICI) of alprostadil 20 microgram
Trial: 16968572
Drug: Travoprost 0.004%
RxNorm normalized name: TRAVOPROST 0.004% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004% ophthalmic solution (Travatan)
Trial: 11228598
Drug: 60% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% oxygen for ca. 10 min at 15 L/min by a face mask (treatment group)
Trial: 9310010
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg isoniazid (INH)
Trial: 9310010
Drug: 18.75 mg
RxNorm normalized name: carbidopa 18.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18.75 mg isoniazid (INH)
Trial: 23691692
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate maintenance infusion of 2 g/hour
Trial: 23691692
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate maintenance infusion of 1 g/hour
Trial: 19773098
Drug: Vero cell
RxNorm normalized name: Vero Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine without aluminum hydroxide adjuvant
Trial: 19773098
Drug: Vero cell
RxNorm normalized name: Vero Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine with aluminum hydroxide adjuvant
Trial: 19773098
Drug: Vero cell
RxNorm normalized name: Vero Cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero cell culture-derived inactivated whole virus influenza A/H5N1 vaccine
Trial: 17522559
Drug: Intramuscular aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular aripiprazole (second injection)
Trial: 14754783
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy for insomnia
Trial: 14754783
Drug: Supervised withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised withdrawal plus cognitive behavior therapy
Trial: 2950148
Drug: Tetracycline 1
RxNorm normalized name: tetracycline 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 1 gram/day for 6 months plus topical therapy (benzoyl peroxide)
Trial: 2950148
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (2 mg cyproterone acetate plus 50 micrograms ethinyl estradiol; spironolactone 100 mg twice daily; isotretinoin 1 mg/kg)
Trial: 30528676
Drug: PF-04457845 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04457845 (4 mg per day)
Trial: 28049937
Drug: Heated water-based
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heated water-based exercise (HEx) training protocol (callisthenic exercises and walking in a heated pool for 1 h, three times weekly for 12 weeks)
Trial: 21080201
Drug: Chemotherapy (vinca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (vinca alkaloids, taxanes, or platina derivatives)
Trial: 19333153
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine 0.5 mg and clonidine 100 microg (CMC)
Trial: 19333153
Drug: Preservative free
RxNorm normalized name: preservative free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative free morphine 0.5 mg (MOR)
Trial: 16697968
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue (GnRH-a) injections during cyclophosphamide therapy
Trial: 16697968
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection of GnRH analogue (GnRH-a) during cyclophosphamide therapy
Trial: 8993085
Drug: Venlafaxine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (maximum dose 225 mg/day)
Trial: 30659771
Drug: Conventional dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosage regimen and formulations
Trial: 18514318
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of overall, inferior, and superior quadrant RNFL thicknesses
Trial: 16583592
Drug: Colgate Regular
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Regular Dental Cream
Trial: 1508114
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intracoronary therapy with streptokinase
Trial: 6389014
Drug: Flupirtine maleate
RxNorm normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine maleate (100 mg, oral doses, up to 4 doses per day for 5 days)
Trial: 6389014
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 g, oral doses, up to 4 doses per day for 5 days)
Trial: 29287749
Drug: Andecaliximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab (400 mg) administered every 2 weeks for a total of 3 intravenous infusions.
Trial: 29287749
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every 2 weeks for a total of 3 intravenous infusions.
Trial: 22633825
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate, 64 mmol/day
Trial: 19341900
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-EVAR treatment)
Trial: 17929300
Drug: Ribavirin for
RxNorm normalized name: Ribavirin for Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin for 72 hours prior to peginterferon alpha‐2a injection